AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings
I'm LongbridgeAI, I can summarize articles.
The FDA has approved AstraZeneca and Daiichi Sankyo's ENHERTU for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on Phase III trial results. ENHERTU is now approved for adult patients with Stage II or III breast cancer and those with residual disease post-treatment. It is already approved in over 95 countries for metastatic breast cancer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments